Veristrat from Biodesix is an example of a serum-based test used in the clinic that can predict response to a second-line biotherapeutic treatment option.
Biodesix is looking to forge pharmaceutical partnerships to increase adoption of the test Veristrat.
Presenting current issues with lung cancer tissue testing, followed by a discussion of Veristrat, Biodesix proteomic serum test for predicted tumor response
The number of studies at this year's European Lung Conference suggest notable progress in personalized medicine as well as the understanding of lung cancer.
A new blood test could improve the use of a popular lung cancer drug called erlotinib by allowing doctors to select which patients will react positively.